Streetbeat News

AMPE

Ampio Pharmaceuticals Inc

http://ampiopharma.com/

CEO

Michael Macaluso

Employees

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

ampio pharmaceuticals inc (ampe) is a biotechnology company located in 5445 dtc pkwy, greenwood village, colorado, united states.

Open

0.00

Mkt cap

Volume

150

High

0.00

P/E Ratio

N/A

52-wk high

2.91

Low

0.00

Div yield

N/A

52-wk low

0.00

Ampio Pharmaceuticals (AMEX:AMPE) reported a Q4 EPS loss of $(2.48), which is an improvement from the $(3.60) per share loss reported in the same quarter last year, marking a 31.11% increase in performance.

Portfolio Pulse from Happy Mohamed

March 28, 2024 | 3:46 am

Ampio Pharmaceuticals has announced its intention to voluntarily delist its shares of common stock from the NYSE American and proceed with SEC deregistration.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 9:13 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Societal CDMO and Enveric Biosciences saw substantial gains, while Kineta and Ironwood Pharmaceuticals faced notable declines. Revance Therapeutics and Castle Biosciences reported their Q4 earnings, influencing their stock performance.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:32 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Enveric Biosciences, Societal CDMO, and NeuroBo Pharmaceuticals were among the top gainers, with Enveric Biosciences leading at a 162.3% increase. On the losing side, Ironwood Pharmaceuticals, Milestone Pharmaceuticals, and Butterfly Network saw notable declines, with Ironwood Pharmaceuticals dropping by 27.7%. Earnings releases influenced some of the stock movements.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:07 pm

In Wednesday's after-market session, several healthcare stocks showed significant movement. Gainers included IGC Pharma, Establishment Labs Holdings, Voyager Therapeutics, Natera, MiMedx Group, and Lexaria Bioscience, with increases ranging from 9.01% to 14.6%. Losers were Butterfly Network, Ampio Pharmaceuticals, ClearPoint Neuro, Schrodinger, GlucoTrack, and SILO Pharma, with decreases ranging from 7.41% to 16.9%. Notably, many companies reported their Q4 earnings, influencing these movements.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:31 pm

Ampio Pharmaceuticals, Inc. (AMPE) has notified H.C. Wainwright & Co., LLC of its decision to terminate their At The Marketing Offering Agreement dated September 18, 2023. This agreement was for an at-the-market equity distribution program. The termination will be effective on March 6, 2024. Additionally, AMPE filed a post-effective amendment to withdraw and remove any unsold or unissued securities under its Registration Statement, including shares covered by the at-the-market offering agreement.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 8:51 pm

Ampiolans announced plans to take immediate actions to preserve its cash to ensure it can fund any options identified by its Board. The company's management and Board are assessing both internal and external options.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:00 pm

Ampio Pharmaceuticals announced that the efficacy results from its nonclinical Pre-IND enabling studies with OA-201 do not support an IND submission, which was anticipated in early 2025. This development could significantly impact the company's research timeline and potential product pipeline.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 10:59 pm

Ampio Pharmaceuticals, Inc. has reached a settlement in principle regarding a pending securities fraud class action lawsuit. The terms of the settlement have not been disclosed, and the agreement is subject to court approval. This development may resolve legal uncertainties for the company, but the financial impact of the settlement is not yet clear.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 9:19 pm

RxSight, Inc. (RXST) shares surged by 20% after providing FY23 and FY24 revenue guidance above estimates and following a price target increase by Needham. Other stocks experienced significant movement, with Harpoon Therapeutics, Inc. (HARP) and Ambrx Biopharma Inc. (AMAM) seeing major gains due to acquisition announcements. Conversely, LumiraDx Limited (LMDX) and Solo Brands, Inc. (DTC) faced steep declines, with LumiraDx facing Nasdaq suspension and Solo Brands lowering its full year 2023 revenue guidance.

Portfolio Pulse from Avi Kapoor

January 08, 2024 | 6:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.